Titan Pharmaceuticals, Inc. (TTNP)
NASDAQ: TTNP · IEX Real-Time Price · USD
6.35
+0.13 (2.09%)
At close: Jul 19, 2024, 4:00 PM
6.31
-0.04 (-0.63%)
Pre-market: Jul 22, 2024, 5:05 AM EDT
Company Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.
It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
The company was founded in 1991 and is based in South San Francisco, California.
Titan Pharmaceuticals, Inc.
| Country | United States |
| IPO Date | Jan 18, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David Elliot Lazar |
Contact Details
Address: 400 Oyster Point Blvd, Suite 505 San Francisco, California 94080 United States | |
| Phone | (650) 244-4990 |
| Website | titanpharm.com |
Stock Details
| Ticker Symbol | TTNP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000910267 |
| CUSIP Number | 888314606 |
| ISIN Number | US8883147055 |
| Employer ID | 94-3171940 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jennifer Kiernan | Executive Assistant to Chief Executive Officer and Investor Communications Coordinator |
| David Elliot Lazar | Chief Executive Officer and Principal Financial Officer |
| Dr. Katherine L. Beebe-DeVarney Ph.D. | President, Chief Operating Officer and Director |
| Mike Fritz | National Sales Director |
| Joe Schrei | Executive Director of Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | RW | Filing |
| Apr 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 3, 2024 | 8-K | Current Report |
| Apr 1, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 8-K | Current Report |
| Feb 8, 2024 | 8-K | Current Report |
| Jan 25, 2024 | 8-K | Current Report |
| Jan 18, 2024 | 8-K | Current Report |